Preclinical and clinical studies have identified that CaEP treatment leads to a release of damage-associated molecular patterns (DAMPs) from necrotising cancer cells, including adenosine-triphosphate (ATP) and high-mobility group box 1 (HMGB1) [1, 5–7]. This evidence concerns the gene HMGB1 and cancer.